What are the first‑line pharmacologic treatment options for bipolar disorder, including acute manic, depressive, and maintenance phases?

Treatment of Bipolar Disorder

First-Line Pharmacotherapy by Phase

For acute mania, initiate lithium, valproate (divalproex), or a second-generation antipsychotic (aripiprazole, risperidone, quetiapine, olanzapine, asenapine, paliperidone, or cariprazine) as monotherapy or in combination. 1

Acute Manic Phase

• Lithium, valproate, and second-generation antipsychotics constitute the primary treatment options for acute mania, with combination therapy (mood stabilizer plus antipsychotic) often superior to monotherapy. 2, 1

• Aripiprazole combined with valproate is specifically recommended as first-line for acute mania and mixed episodes, particularly when irritability and aggression are prominent. 3

• Target valproate plasma concentrations of 85–125 µg/mL by initiating at approximately 25 mg/kg/day (2000–2500 mg for typical adults) and increasing by 500 mg every 2–3 days until therapeutic levels are achieved. 3

• Lithium is FDA-approved down to age 12 years for acute mania and has unique antisuicide effects that distinguish it from other mood stabilizers. 2, 4

Acute Depressive Phase

For bipolar depression, use quetiapine, lurasidone (alone or with lithium/divalproex), lithium, lamotrigine, or adjunctive lamotrigine as first-line options. 1

• Quetiapine and the combination of olanzapine plus fluoxetine have FDA approval for bipolar depression in adults. 2, 1

• Avoid antidepressant monotherapy or dose escalation during depressive episodes, as antidepressants can destabilize mood or precipitate manic switches without adequate mood stabilizer coverage. 3

• Lamotrigine shows efficacy but requires slow titration due to serious rash risk; it is generally well-tolerated gastrointestinally. 3, 5

Maintenance Phase

Continue lithium, quetiapine, divalproex, lamotrigine, asenapine, or aripiprazole for maintenance treatment, prioritizing agents effective in the acute phase. 1

• Maintain treatment for at least 2 years after achieving mood stabilization to sustain remission and prevent relapse. 3

• Lithium and valproate remain cornerstones of long-term prophylaxis, with lithium being the gold standard for typical bipolar I disorder and valproate more effective for atypical presentations (mixed states, rapid cycling). 6, 1

• When mood stabilizer monotherapy proves insufficient for maintenance, quetiapine or aripiprazole represent the most advisable adjunctive strategies based on safety and tolerability profiles. 6

Ineffective Agents to Avoid

Do not use gabapentin or topiramate as mood stabilizers—controlled trials demonstrate lack of efficacy. 3

• Gabapentin at 1800 mg/day has not shown benefit in controlled bipolar studies and should not be prescribed for mood stabilization. 3

• Topiramate at 50 mg/day lacks efficacy in adult trials and shows only equivocal results in younger populations. 3

• Taper and discontinue these ineffective agents once valproate dosing is optimized to reduce polypharmacy burden. 3

Critical Clinical Pitfalls

Do not add a second antipsychotic before optimizing the mood stabilizer dose and plasma levels, as combination antipsychotic therapy increases adverse effects without clear added benefit. 3

• Ensure adequate antimanic coverage (optimized valproate or lithium) before addressing comorbid anxiety or secondary symptoms. 3

• Do not increase antidepressant dosing or introduce new antidepressants during manic or mixed episodes, as this exacerbates mood instability. 3

Monitoring Requirements

Obtain valproate plasma levels 5–7 days after any dose change, targeting 85–125 µg/mL; repeat liver function tests and complete blood count with platelets before initiation and every 3–6 months during therapy. 3

• Conduct weekly clinical assessments for mood improvement, manic switch, worsening irritability, or suicidal ideation during acute treatment. 3

• When combining valproate with atypical antipsychotics, monitor body mass index and metabolic parameters (fasting glucose, lipid profile) every 3–6 months. 3

• For aripiprazole, assess for extrapyramidal symptoms (lower risk than typical antipsychotics) and metabolic parameters given its relatively favorable profile. 3

Adjunctive Psychosocial Interventions

Incorporate psychoeducation and evidence-based psychotherapy (cognitive-behavioral therapy, family-focused therapy, interpersonal and social rhythm therapy) as adjuncts to pharmacotherapy across all phases. 7, 8

• Psychosocial interventions enhance medication adherence, improve personal functioning, and reduce relapse rates when combined with pharmacological treatment. 7